ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical
stage specialty biopharmaceutical company developing first-in-class
drugs for treatment of patients with renal and inflammatory
diseases who have unmet medical needs, announces that Dr. Richard
J. Glassock has joined ZyVersa’s Renal Scientific Advisory Board.
“We are honored that Dr. Glassock, an internationally recognized
authority in the field of glomerular disease, is joining our
Scientific Advisory Board,” stated Dr. Pablo Guzman, ZyVersa’s
Chief Medical Officer and Chairman of the Renal Scientific Advisory
Board. “We look forward to his invaluable insights and
contributions as we advance our clinical development program for
renal Cholesterol Efflux Mediator VAR 200.”
Dr. Glassock is currently Professor Emeritus at the David Geffen
School of Medicine at UCLA, and an independent medical consultant.
His main interests are in glomerular disease, chronic kidney
disease, and clinical nephrology. Dr. Glassock has published over
750 original papers, books, book chapters, and reviews. He is the
past-president of the American Society of Nephrology and the
National Kidney Foundation (USA), and past-Chairman of the American
Board of Internal Medicine. Dr. Glassock was the former Chair of
the Departments of Medicine at the University of Kentucky
(1992-1999) and Harbor-UCLA Medical Center (1980-1992). He is a
Master of The American College of Physicians and a Fellow of The
Royal College of Physicians (UK). Dr. Glassock has won numerous
prestigious awards from various nephrology and medical
associations, and from UCLA.
Dr. Glassock joins ZyVersa’s current team of prominent
Scientific Advisors:
- Sharon G. Adler, MD: Professor of Medicine at
David Geffen School of Medicine, UCLA, Chief, Division of
Nephrology and Hypertension at Harbor-UCLA Medical Center, and
Program Director, Nephrology Fellowship Training Program at
Harbor-UCLA Medical Center
- Daniel C. Cattran, MD, FRCP: Professor of
Medicine, University of Toronto
- Fernando C. Fervenza, MD, PhD: Professor of
Medicine, Mayo Graduate School of Medicine, and Director of the
Nephrology Collaborative Group
- Alessia Fornoni, MD, PhD: Professor of
Medicine and Chief of Katz Family Division of Nephrology and
Hypertension at University of Miami Miller School of Medicine
- Pablo A. Guzman, MD, FAAC: Chief Medical
Officer and Chairman of Renal Scientific Advisory Board at ZyVersa
Therapeutics
- Marlene Haffner, MD, MPH: Principal and
Founder of Orphan Solutions and former Director of Orphan Products
Development at FDA
“Enlisting the insights and strategic guidance of our renowned
scientific advisory board is key to achieving our mission to
develop transformative drug therapies for patients with renal
disease,” said Stephen C. Glover, ZyVersa’s Co-founder, Chief
Executive Officer, and Chairman. “We appreciate their expertise and
time to support our mission.”
About VAR 200
Cholesterol Efflux Mediator™ VAR 200
(2-hydroxypropyl-beta-cyclodextrin, 2HPβCD) is a phase 2a-ready
drug in development to ameliorate renal lipid accumulation that
damages the kidneys’ filtration system, leading to kidney disease
progression. VAR 200 passively and actively removes excess lipids
from the kidney.
Preclinical studies with VAR 200 in animal models of FSGS,
Alport syndrome, and diabetic kidney disease demonstrate that
removal of excess cholesterol and lipids from kidney podocytes
protects against structural damage and reduces excretion of protein
in the urine (proteinuria).
The lead indication for VAR 200 is orphan kidney disease focal
segmental glomerulosclerosis (FSGS). VAR 200 has potential to treat
other glomerular diseases, including orphan Alport syndrome and
diabetic kidney disease.
About ZyVersa Therapeutics, Inc.
ZyVersa is a clinical stage specialty biopharmaceutical company
leveraging advanced, proprietary technologies to develop
first-in-class drugs. Our focus is on patients with renal or
inflammatory diseases who have significant unmet medical needs. Our
development pipeline includes phase 2a-ready Cholesterol Efflux
Mediator™ VAR 200 in development to alleviate damaging
accumulation of cholesterol and lipids in the filtering system of
the kidneys. The lead indication is treatment of rare kidney
disease, focal segmental glomerulosclerosis. VAR 200 has potential
to treat other kidney diseases, including Alport syndrome and
diabetic kidney disease. ZyVersa’s pipeline also includes
proprietary inflammasome ASC inhibitor IC 100 that blocks
initiation and perpetuation of damaging inflammation associated
with a multitude of inflammatory diseases. IC 100 has potential to
treat many different CNS and other inflammatory diseases. For more
information, please visit www.zyversa.com.
Cautionary Statement Regarding Forward-Looking
Statements
Certain statements contained in this press release regarding
matters that are not historical facts, are forward-looking
statements within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended, and the Private Securities
Litigation Reform Act of 1995. These include statements regarding
management’s intentions, plans, beliefs, expectations, or forecasts
for the future, and, therefore, you are cautioned not to place
undue reliance on them. No forward-looking statement can be
guaranteed, and actual results may differ materially from those
projected. ZyVersa Therapeutics, Inc (“ZyVersa”) uses words such as
“anticipates,” “believes,” “plans,” “expects,” “projects,”
“future,” “intends,” “may,” “will,” “should,” “could,” “estimates,”
“predicts,” “potential,” “continue,” “guidance,” and similar
expressions to identify these forward-looking statements that are
intended to be covered by the safe-harbor provisions. Such
forward-looking statements are based on ZyVersa’s expectations and
involve risks and uncertainties; consequently, actual results may
differ materially from those expressed or implied in the statements
due to a number of factors, including ZyVersa’s plans to develop
and commercialize its product candidates, the timing of initiation
of ZyVersa’s planned preclinical and clinical trials; the timing of
the availability of data from ZyVersa’s preclinical and clinical
trials; the timing of any planned investigational new drug
application or new drug application; ZyVersa’s plans to research,
develop, and commercialize its current and future product
candidates; the clinical utility, potential benefits and market
acceptance of ZyVersa’s product candidates; ZyVersa’s
commercialization, marketing and manufacturing capabilities and
strategy; ZyVersa’s ability to protect its intellectual property
position; and ZyVersa’s estimates regarding future revenue,
expenses, capital requirements and need for additional
financing.
New factors emerge from time-to-time, and it is not possible for
ZyVersa to predict all such factors, nor can ZyVersa assess the
impact of each such factor on the business or the extent to which
any factor, or combination of factors, may cause actual results to
differ materially from those contained in any forward-looking
statements. Forward-looking statements included in this press
release are based on information available to ZyVersa as of the
date of this press release. ZyVersa disclaims any obligation to
update such forward-looking statements to reflect events or
circumstances after the date of this press release, except as
required by applicable law.
This press release does not constitute an offer to sell, or the
solicitation of an offer to buy, any securities.
Corporate and IR ContactKaren CashmereChief
Commercial
Officerkcashmere@zyversa.com786-251-9641
Media ContactsCasey
McDonaldcmcdonald@tiberend.com646-577-8520
Dave SchemeliaDschemelia@tiberend.com609-468-9325
ZyVersa Therapeutics (NASDAQ:ZVSA)
Historical Stock Chart
From Nov 2023 to Dec 2023
ZyVersa Therapeutics (NASDAQ:ZVSA)
Historical Stock Chart
From Dec 2022 to Dec 2023